# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Citigroup analyst David Hoang downgrades Sarepta Therapeutics (NASDAQ:SRPT) from Buy to Neutral and raises the price target ...
Morgan Stanley analyst Matthew Harrison maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Overweight and raises the price ...
Evercore ISI Group analyst Gavin Clark-Gartner maintains Sarepta Therapeutics (NASDAQ:SRPT) with a In-Line and raises the pr...
BMO Capital analyst Kostas Biliouris maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and raises the price tar...
Leerink Partners analyst Mani Foroohar maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and raises the price t...
Top performers last week were SRPT (+29.50%), SIRI (+16.73%), TOST (+15.57%), GILD (+12.62%), CHWY (+10.59%), ACN (+9.80%), DKN...